Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02332889 · ClinicalTrials.gov registry record · Phase 1
Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs
A Phase 1 study, sponsored by University of Louisville.
- Terminated
- Registry status
- Phase 1
- Development phase
- 1
- Enrollment target
NCT02332889 is a Phase 1 study that was terminated before completion, run by University of Louisville. The registered enrollment target is 1 participants.
The verdict
NCT02332889, a Phase 1 study, was terminated before completion, sponsored by University of Louisville.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 1 participants
- Enrollment target
Study Summary
The main purpose of this study is to determine the safety of using the combination of decitabine and a cancer vaccine plus Hiltonol. The vaccine will be made from the subject's blood cells and is designed to interact in the subject's body with cells that are programmed to fight specific tumor proteins NY-ESO-1, Melanoma Antigen Gene-A1 (MAGE-A1) and Melanoma Antigen Gene-A3 (MAGE-A3). The decitabine will be given to increase the amount and activity of these cancer proteins on the surface of tumor cells to increase the possibility that the vaccine will stimulate cells to act against the tumor cells. Subjects will be assessed to determine how these tumors respond to the treatment.
Interventions
- BIOLOGICAL Vaccine (autologous dendritic cells)
- DRUG Decitabine and Hiltonol
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1 participants |
| Start Date | 2015-04 |
| Est. Completion | 2016-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02332889
The ClinicalTrials.gov registry entry for NCT02332889 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 1 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Louisville, which has 217 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Vaccine (autologous dendritic cells) is the first listed.
NCT02332889 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02332889 about?
NCT02332889 is a clinical study titled "Phase I/II: Decitabine/Vaccine Therapy in Relapsed/Refractory Pediatric High Grade Gliomas/Medulloblastomas/CNS PNETs". The main purpose of this study is to determine the safety of using the combination of decitabine and a cancer vaccine plus Hiltonol. The vaccine will be made from the subject's blood cells and is designed to interact in the subject's body with cells that are programmed to fight specific tumor protei...
What is the current status of trial NCT02332889?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 1 participants. The study started on 2015-04. Estimated completion is 2016-07.
What interventions are being tested in trial NCT02332889?
The interventions under investigation include: Vaccine (autologous dendritic cells) (BIOLOGICAL), Decitabine and Hiltonol (DRUG).
Who is sponsoring clinical trial NCT02332889?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.